Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development stage programs.

Feb 27, 2025 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.

Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.

Feb 27, 2025 · Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “We achieved significant revenue growth in 2024 driven by strong momentum across our major commercial programs,” said Todd Davis, CEO of Ligand.

Dec 10, 2024 · At today’s event, Ligand’s senior management team will highlight: Ligand’s transformation over the past two years into a profitable, diversified, and infrastructure light organization that enables investors to participate in the innovation and promise of the biotech industry while avoiding concentrated binary risk

Todd Davis is Chief Executive Officer of Ligand and has served on the company’s Board of Directors since 2007. He has more than 30 years of operational and investment experience and has been involved in more than $4 billion in healthcare financings over his career.

Feb 25, 2025 · Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications.

Jun 18, 2024 · Ligand will now collect commercial royalties on six products developed with the Pfenex Expression Technology, including Merck’s CAPVAXIVE and VAXNEUVANCE ®, Jazz Pharmaceuticals’ RYLAZE ®, Alvogen’s Teriparatide Injection, and Serum Institute of India’s Pneumosil ® and MenFive ® vaccines. About Ligand Pharmaceuticals

Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development-stage programs. The assets in our portfolio include treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten ...

Jul 8, 2024 · QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the beginning of 2023. Transaction will be immediately accretive to Ligand EPS by an estimated $1.00 per share on an annualized basis with a $0.50 impact to 2024. Ligand increases 2024 adjusted EPS guidance range by 17% to $5.00-$5.50 1